Lan, P T Aedo, A R Landgren, B M Johannisson, E Diczfalusy, E
Published in
Contraception
The effect of a single dose of 150 mg depomedroxyprogesterone acetate (DMPA) on pituitary, ovarian, and endometrial function was assessed in relation to the peripheral levels of the compound in 8 women. The levels of DMPA, follitropin (FSH), lutropin (LH), prolactin, estradiol (E2), and progesterone (P) were measured 3 times/week during a pretreatm...
Kokko, E Jänne, O Kauppila, A Vihko, R
Published in
American journal of obstetrics and gynecology
Fraser, I S
Published in
Clinical reproduction and fertility
Injectable hormonal preparations can be highly effective and satisfactory contraceptives. The 2 main preparations available today are depo medroxyprogesterone acetate (DMPA) and norethindrone enanthate (NET-EN), but several other approaches are currently under clinical trial. Injectable contraceptives have some unique advantages which give them jus...
McGoldrick, I A
Published in
Papua and New Guinea medical journal
In this discussion of Depo-Provera (DMPA) attention is directed to the following: pharmacology and mode of action; clinical considerations; cervical dysplasia; breast cancer; and endometrial carcinoma. DMPA, a microcrystalline suspension of medroxy-progesterone acetate, is used widely around the world as a contraceptive, particularly in developing ...
Pérez-Palacios, G Fernández-Aparicio, M A Medina, M Zacarías-Villareal, J Ulloa-Aguirre, A
Published in
Acta endocrinologica
Wigington, S
Published in
Nursing times
The contraceptive effect of Depo-Provera or medroxyprogesterone acetate, a long-acting injectable progestogen, has been mainly attributed to its ability to prevent ovulation through its action on the hypothalamic pituitary axis, reducing the levels of plasma gonadotropin, progesterone, and estradiol, and suppressing the midcycle surge of luteinizin...
Guin, A K Datta, S C Das, S Sengupta, D
Published in
Indian journal of biochemistry & biophysics
Clinical experimentation was carried out to assess the effect of nonantiovulatory doses of norethindrone and depo provera on implantation in rats. Norethindrone in doses of 25 and 50 mcg and depo provera in doses of 5 and 10 mcg, administered from day 0-5 of pregnancy, prevented implantation. Lower doses of either drug had no effect on implantation...
Guin, A K Das, S Datta, S C Dey, S Sengupta, D
Published in
Indian journal of experimental biology
Clinical experimentation was carried out to assess the antiestrogenic effects of norethindrone and depo provera administered at a dose schedule which did not inhibit ovulation. The laboratory procedures employed are explained and results tabulated. Norethindrone at doses of 10, 25, and 50 ug/rat daily for 10 days and depo-provera at doses of 1, 5, ...
Finn, C A Martin, L
Published in
The Journal of endocrinology
Three experiments were conducted to evaluate the duration of activity of a long-acting progestin, medroxyprogesterone acetate: 1) induction of stromal mitosis in the endometrium; 2) implantation of blastocysts; and 3) inhibition of ovulation. In the 1st experiment, randomly bred albino mice were ovariectomized and injected with MPA 1 week later. Th...
Izquierdo, J A Savini, C Borghi, E Rabiller, G Costas, S Justel, E
Published in
Pharmacological research communications
A clinical study with 361 female rats was conducted to elucidate the mechanism whereby MPA (medroxyprogesterone acetate) lowers 5-HT/5-HIAA ratio in the brain area and the possible role of serotoniergic mechanisms. In addition, the participation of MAO (monoamino oxidase) system and the effects of some steroids were studied in order to establish a ...
